{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:10:08Z","timestamp":1786122608500,"version":"build-2736575974"},"reference-count":24,"publisher":"Media Sphere Publishing House","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2026,8,7]]},"abstract":"<jats:p>Objective. To evaluate the efficacy and safety of Ranquilon1 at 6 mg daily, compared with Afobazol (fabomotizole) at 30 mg daily, for the treatment of patients with anxiety associated with neurasthenia and adjustment disorders. Material and methods. The clinical study included 200 patients diagnosed with anxiety associated with neurasthenia (F48.0) or adjustment disorder (F43.2). All participants had a Hamilton Anxiety Rating Scale (HARS) score of 18\u201424, demonstrated significant asthenia on the Multidimensional Fatigue Inventory (MFI-20) (score over 50), and scored at least 4 on the Clinical Global Impression-Severity (CGI-S) subscale. Participants were randomly assigned to two groups: Group 1 consisted of 100 patients receiving Ranquilon 1 mg tablets at 6 mg\/day (2 tablets three times daily) for 28 days, while Group 2 consisted of 100 patients receiving Afobazol (fabomotizole) 10 mg tablets at 30 mg\/day (1 tablet three times daily) for the same duration. The assessment of therapeutic response used the HARS, the Psychological Stress Measure (PSM-25) to evaluate stress levels, the MFI-20 scale to assess asthenia, and the CGI-S subscale to assess the severity of the condition. Monitoring for adverse events (AEs), serious adverse events (SAEs), and clinically significant changes in vital signs, laboratory tests, and ECG parameters was used for safety assessment. Results. The proportion of responders with a 50% or greater reduction in mean HARS scores at Visit 3 (Day 29\u00b11) compared to baseline (Visit 0) was statistically higher (p&lt;0.043) in Group 1 (63.3%, n=62) vs. Group 2 (49.0%, n=49). All secondary efficacy criteria further demonstrated statistically significant advantages for Group 1 compared to Group 2 (p&lt;0.05). In total, 29 AEs were reported in 14.0% (n=44) of patients, including 16 AEs in 16.0% (n=16) of patients from Group 1 and 13 AEs in 12.0% (n=12) of patients from Group 2. There was no significant difference between the treatment groups in the number of patients with AEs (p=0.4150). Both groups reported only mild AEs, with none serious, severe, or fatal, and none leading to discontinuation of study treatment. No clinically significant abnormalities were observed in vital signs, laboratory tests, or ECG assessments. Conclusion. Ranquilon 1 mg tablets at 6 mg\/day demonstrate greater efficacy than Afobazol 10 mg tablets at 30 mg\/day in alleviating anxiety associated with neurasthenia and adjustment disorders. The safety profile of Ranquilon is favorable and comparable to that of Afobazol.<\/jats:p>","DOI":"10.17116\/jnevro202612607151","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:16:52Z","timestamp":1786101412000},"page":"51","source":"Crossref","is-referenced-by-count":0,"title":["Comparative study of the efficacy and safety of Ranquilon and Afobazol in the treatment of patients with anxiety associated with neurasthenia and adjustment disorders. (Results of an open, randomized, multicenter, phase IV clinical study)"],"prefix":"10.17116","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8798-3702","authenticated-orcid":false,"given":"T.A.","family":"Karavayeva","sequence":"first","affiliation":[{"name":"V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology","place":["St. Petersburg, Russia"]},{"name":"Saint Petersburg State University","place":["St. Petersburg, Russia"]},{"name":"Saint Petersburg State Pediatric Medical University","place":["St. Petersburg, Russia"]},{"name":"N.N. Petrov National Medical Research Centre for Oncology","place":["St. Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7146-2024","authenticated-orcid":false,"given":"A.N.","family":"Barinov","sequence":"additional","affiliation":[{"name":"Saratov State Medical University named after V.I. Razumovsky","place":["Saratov, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-429X","authenticated-orcid":false,"given":"I.V.","family":"Egorov","sequence":"additional","affiliation":[{"name":"ANO \u00abInstitute of Integrative Family Therapy\u00bb","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6573-4169","authenticated-orcid":false,"given":"E.Yu.","family":"Ebzeeva","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuing Professional Education","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0532-5727","authenticated-orcid":false,"given":"K.A.","family":"Ishchenko","sequence":"additional","affiliation":[{"name":"JSC \u00abValenta Pharm\u00bb","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202612607151-1","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-012-1842-1"},{"key":"key-10.17116\/jnevro202612607151-2","unstructured":"Kolik LG, Garibova TL, Litvinova SA, et al. The absence of tolerance and withdrawal syndrome after the treatment with the new L-tryptophane-containing dipeptide anxiolytic GB-115. Vestnik Rossijskoj akademii medicinskih nauk. 2011;7:37-42. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-3","unstructured":"Otkrytoe klinicheskoe issledovanie I fazy po izucheni- yu vliyaniya priema pishchi na farmakokinetiki preparata Ranquilon, tabletki, 1 mg, u zdorovyh dobrovol\u2019cev pri odnokratnom primenenii. Protokol issledovaniya RAN-01-02-2021. Otchet o klinicheskom issledovanii I fazy 18.03.2022. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-4","unstructured":"Dvojnoe slepoe, randomizirovannoe, placebokontroliruemoe, mnogocentrovoe issledovanie po izucheniyu klinicheskoj effektivnosti i bezopasnosti preparata Ranquilon, tabletki, u pacientov s trevozhnymi sostoyaniyami pri nevrastenii i rasstrojstvah adaptacii. Protokol issledovaniya RAN-02-01-2020. Otchet o klinicheskom issledovanii II fazy 29.04.2022. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-5","doi-asserted-by":"publisher","DOI":"10.32756\/0869-5490-2023-4-36-40"},{"key":"key-10.17116\/jnevro202612607151-6","doi-asserted-by":"publisher","DOI":"10.32756\/0869-5490-2023-1-49-55"},{"key":"key-10.17116\/jnevro202612607151-7","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201911908153"},{"key":"key-10.17116\/jnevro202612607151-8","unstructured":"Dvojnoe slepoe, randomizirovannoe, placebo-kontroliruemoe, mnogocentrovoe klinicheskoe issledovanie III fazy po izucheniyu klinicheskoj effektivnosti i bezopasnosti preparata Ranquilon, tabletki, 1 mg u pacientov s trevozhnymi sostoyaniyami pri nevrastenii i rasstrojstvah adaptacii. Protokol issledovaniya RAN-03-03-2022. Otchet o klinicheskom issledovanii III fazy 20.02.2023 g. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-9","doi-asserted-by":"crossref","unstructured":"Karavayeva TA, Krupitsky EM, Barinov AN, et al. Efficacy and safety of Ranquilon\u00ae in the therapy of patients with anxiety associated with neurasthenia and adjustment disorder: results of the double-blind, randomized, placebo-controlled, multicenter, phase 3 clinical trial. V.M. Bekhterev review of psychiatry and medical psychology. 2024;58:4-2:78-99. (In Russ.)","DOI":"10.31363\/2313-7053-2024-1047"},{"key":"key-10.17116\/jnevro202612607151-10","unstructured":"Open-label, comparative, randomized, multicenter phase IV clinical trial to evaluate the clinical efficacy and safety of the drug Ranquilon, tablets, 1 mg, in patients with anxiety disorders due to neurasthenia and adjustment disorders. Protocol RAN-04-05-2024. Phase IV clinical trial report 30.09.2025 (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-11","unstructured":"Efficacy and safety of Ranquilon in patients with anxiety disorders due to neurasthenia and adjustment Disorders. [clinicaltrials.gov]. clinicaltrials; 2025. Available:  https:\/\/clinicaltrials.gov\/study\/NCT06843044?term=Ranquilon&rank=1"},{"key":"key-10.17116\/jnevro202612607151-12","unstructured":"https:\/\/lk.regmed.ru\/Register\/EAEU_SmPC General characteristics of the medical product Ranquilon\u00ae (N-(6-phenylhexanoyl)glycyl-L-tryptophan amide), tablets 1 mg. [lk.regmed.ru]. lk.regmed; 2023. (In Russ.). Available: @@https:\/\/lk.regmed.ru\/Register\/EAEU_SmPC"},{"key":"key-10.17116\/jnevro202612607151-13","unstructured":"https:\/\/lk.regmed.ru\/Register\/EAEU_SmPC General characteristics of the medical product Afobazol\u00ae (fabomotizole), tablets 10 mg. [lk.regmed.ru]. lk.regmed; 2024. (In Russ.). Available: @@https:\/\/lk.regmed.ru\/Register\/EAEU_SmPC"},{"key":"key-10.17116\/jnevro202612607151-14","unstructured":"World Health Organisation (WHO): The ICD-10 classification of mental and behavioral disorders: Clinical description and diagnostic guidelines (ICD-10). Geneva: WHO; 1992"},{"key":"key-10.17116\/jnevro202612607151-15","unstructured":"Psihicheskie rasstrojstva i rasstrojstva povedeniya (F00-F99). (Klass V MKB-10, adaptirovannyj dlya ispol\u2019zovaniya v Rossijskoj Federacii). Pod obshchej redakciej Kazakovceva B.A., Gollanda V.B. M.: Minzdrav Rossii, 1998. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-16","unstructured":"Chutko LS, Baranova IA. Neurasthenia. Meditsinskiy sovet. 2009;(4):23-24. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-17","unstructured":"Dadasheva KN, Agafonov BV, Dadasheva MN, et al. Asthenic syndrome in general practice: therapy possibilities. RMJ. Medicinskoe obozrenie. 2019;4(II):91-95. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-18","unstructured":"Vasil\u2019eva AV, Karavaeva TA. Bolezn\u2019 i zdorov\u2019e, psihoterapiya i soperezhivanie. Pod obshch. red. N.G. Neznanova; avt-sost.: SPb.: OOO Izdatel\u2019skijdom \u00abAlef-Press\u00bb, 2019. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-19","unstructured":"Karavaeva TA, Vasil\u2019eva AV. Psihoterapiya. Uchebnik. pod red. A.V. Vasil\u2019evoj, T.A. Karavaevoj, N.G. Neznanova. Moskva: GEOTAR-Media, 2022. (In Russ.)"},{"key":"key-10.17116\/jnevro202612607151-20","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0063-8"},{"key":"key-10.17116\/jnevro202612607151-21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2024.100680"},{"key":"key-10.17116\/jnevro202612607151-22","doi-asserted-by":"publisher","DOI":"10.1139\/jpn.0322"},{"key":"key-10.17116\/jnevro202612607151-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2012.05.022"},{"key":"key-10.17116\/jnevro202612607151-24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.69333"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:17:04Z","timestamp":1786101424000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2026\/7\/1199772982026071051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,8,7]]}},"alternative-id":["10.17116\/jnevro202612607151"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202612607151","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}